L’Oreal Falls Short On Safety, Efficacy, Adverse Event Data
This article was originally published in The Tan Sheet
Executive Summary
FDA says it needs additional data from L’Oreal on safety, efficacy and adverse events to determine GRASE for drometrizole trisiloxane.
You may also be interested in...
Adverse-Event Data Requirement Among Sunscreen TEA Bugs – FDA
The significant time and resources necessary to amend the monograph are one reason for FDA’s slow response to time and extent applications to add ingredients to the OTC sunscreen monograph, agency officials say. Another reason may be flawed data requirements in the application process, with the requirement for adverse-event reports cited as a particular challenge for both sponsors and the agency.
Senators Optimistic As Sunscreen Bill Heads For HELP Committee Markup
Ahead of a Sept. 17 committee markup of the Senate’s Sunscreen Innovation Act, bill sponsors and stakeholders held a briefing on Capitol Hill to generate support for the legislation, which has already passed in the House. The bill, S. 2141, has 15 co-sponsors and is expected to advance through committee to the Senate floor.
Flaws In TEA Process Delay Reviews, Monograph Changes – FDA
The significant time and resources necessary to amend the monograph are one reason for FDA’s slow response to time and extent applications to add ingredients to the OTC sunscreen monograph, agency officials say. Another reason may be flaws in data required in the application process.